A metabolomics-based approach for predicting stages of chronic kidney disease

Biochemical and Biophysical Research Communications

Volumn 445, Issue 2, 2014, Pages 412-416

  Kobayashi, Toshihiro ^a   Yoshida, Tatsunari ^b   Fujisawa, Tatsuya ^c   Matsumura, Yuriko ^a   Ozawa, Toshihiko ^a,d   Yanai, Hiroyuki ^a   Iwasawa, Atsuo ^a   Kamachi, Toshiaki ^a   Fujiwara, Kouichi ^c   Kohno, Masahiro ^a   Tanaka, Noriaki ^c  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^b SHIMADZU CORPORATION   (Japan)

^c Kiyokai Tanaka Kitanoda Hospital   (Japan)

^d YOKOHAMA COLLEGE OF PHARMACY   (Japan)

Author keywords

CKD; Cystatin C; GFR; LC MS; OPLS

Indexed keywords

ADENOSINE DERIVATIVE; ALPHA N ACETYLARGININE; ARGININE DERIVATIVE; BIOLOGICAL MARKER; CYSTATIN C; CYTIDINE DERIVATIVE; GLUTAMINE DERIVATIVE; GUANOSINE DERIVATIVE; HIPPURIC ACID; INDICAN; KYNURENINE; N 15 HIPPURIC ACID; N 2,N 2 DIMETHYLGUANOSINE; N 4 ACETYLCYTIDINE; N 6 CARBAMOYLTHREONYLADENOSINE; PHENYLACETYLGLUTAMINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ESTIMATED GLOMERULAR FILTRATION RATE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY;

CKD; CYSTATIN C; GFR; LC/MS; OPLS;

ADULT; AGED; AGED, 80 AND OVER; CHROMATOGRAPHY, LIQUID; CYSTATIN C; EARLY DIAGNOSIS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; LINEAR MODELS; MALE; MASS SPECTROMETRY; METABOLOMICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84896076347     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.02.021     Document Type: Article

References (17)

1. R. Vanholder, G. Glorieux, R. De Smet, and N. Lameire European Uremic Toxin Work Group, New insights in uremic toxins Kidney Int. Suppl. 84 2003 S6 10
2. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N. Engl. J. Med. 351 2004 1296 1305
3. T. Ninomiya, Y. Kiyohara, M. Kubo, Y. Tanizaki, Y. Doi, K. Okubo, Y. Wakugawa, J. Hata, Y. Oishi, K. Shikata, K. Yonemoto, H. Hirakata, and M. Iida Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study Kidney Int. 68 2005 228 236 (Pubitemid 43181380)
4. A. Levey, K.-U. Eckardt, Y. Tsukamoto, A. Levin, J. Coresh, J. Rossert, D. De Zeeuw, T. Hostetter, N. Lameire, and G. Eknoyan Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int. 67 2005 2089 2100 (Pubitemid 41623371)
5. M. Horio, E. Imai, Y. Yasuda, T. Watanabe, and S. Matsuo Performance of GFR equations in Japanese subjects Clin. Exp. Nephrol. 17 2013 352 358
6. C. Peralta, R. Katz, M. Sarnak, J. Ix, L. Fried, I. De Boer, W. Palmas, D. Siscovick, A. Levey, and M. Shlipak Cystatin C identifies chronic kidney disease patients at higher risk for complications J. Am. Soc. Nephrol. 22 2011 147 155
7. M. Shlipak, K. Matsushita, J. Ärnlöv, L. Inker, R. Katz, K. Polkinghorne, D. Rothenbacher, M. Sarnak, B. Astor, J. Coresh, A. Levey, and R. Gansevoort C.K.D.P. Consortium, Cystatin C versus creatinine in determining risk based on kidney function N. Engl. J. Med. 369 2013 932 943
8. M. Yashiro, T. Kamata, H. Segawa, Y. Kadoya, T. Murakami, and E. Muso Comparisons of cystatin C with creatinine for evaluation of renal function in chronic kidney disease Clin. Exp. Nephrol. 13 2009 598 604
9. K. Saito, S. Fujigaki, M. Heyes, K. Shibata, M. Takemura, H. Fujii, H. Wada, A. Noma, and M. Seishima Mechanism of increases in l-kynurenine and quinolinic acid in renal insufficiency Am. J. Physiol. Renal Physiol. 279 2000 F565 572
10. E. Sato, M. Kohno, M. Yamamoto, T. Fujisawa, K. Fujiwara, and N. Tanaka Metabolomic analysis of human plasma from haemodialysis patients Eur. J. Clin. Invest. 41 2011 241 255
11. T. Niwa Update of uremic toxin research by mass spectrometry Mass Spectrom. Rev. 30 2011 510 521
12. T. Toyohara, Y. Akiyama, T. Suzuki, Y. Takeuchi, E. Mishima, M. Tanemoto, A. Momose, N. Toki, H. Sato, M. Nakayama, A. Hozawa, I. Tsuji, S. Ito, T. Soga, and T. Abe Metabolomic profiling of uremic solutes in CKD patients Hypertens. Res. 33 2010 944 952
13. K. Kikuchi, Y. Itoh, R. Tateoka, A. Ezawa, K. Murakami, and T. Niwa Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878 2010 2997 3002
14. K. Kikuchi, Y. Itoh, R. Tateoka, A. Ezawa, K. Murakami, and T. Niwa Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spectrometry J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878 2010 1662 1668
15. T. Kobayashi, Y. Matsumura, T. Ozawa, H. Yanai, A. Iwasawa, T. Kamachi, K. Fujiwara, N. Tanaka, and M. Kohno Exploration of novel predictive markers in rat plasma of the early stages of chronic renal failure Anal. Bioanal. Chem. 406 2014 1365 1376 10.1007/s00216-013-7472-2
16. Y.-Y. Zhao, X.-L. Cheng, F. Wei, X.-Y. Xiao, W.-J. Sun, Y. Zhang, and R.-C. Lin Serum metabonomics study of adenine-induced chronic renal failure in rats by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry Biomarkers 17 2012 48 55
17. T. Niwa Mass spectrometry in the search for uremic toxins Mass Spectrom. Rev. 16 1997 307 332 (Pubitemid 127656255)